title: Abandoning "TAP" as treatment of metastatic endometrial cancer: a serious example of the consequences resulting from the failure to adequately define the question being addressed in a phase 3 trial.
authors.affiliation: Cancer Treatment Centers of America, Eastern Regional Medical Center, 1331 East Wyoming Avenue, Philadelphia, PA 19124, USA. Maurie.Markman@ctca-hope.com
authors.forename: Maurie
authors.initials: M
authors.lastname: Markman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D004317:Doxorubicin / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D017239:Paclitaxel; D002945:Cisplatin